Synlogic Inc. (NASDAQ: SYBX) recently experienced a significant drop in short interest during the month of August. As of August 31st, there were 192,400 shares being shorted, which is a decrease of 25.7% from the previous total of 259,100 shares. With an average daily trading volume of 188,100 shares, the short-interest ratio is currently 1.0 days. Around 0.4% of the company’s shares are currently being short sold.
Wall Street analysts have provided their opinions on Synlogic Inc. Chardan Capital reaffirmed a “buy” rating and issued a price objective of $6.00, while HC Wainwright also reaffirmed a “buy” rating with a price objective of $5.00.
Synlogic Inc. stock saw an increase of 10.0% on the Nasdaq exchange, trading at $0.37. The stock’s 50-day simple moving average is $0.49, and the two-hundred-day simple moving average is $0.54. Synlogic’s one-year low is $0.24, and its one-year high is $1.35.
In its latest quarterly earnings results, Synlogic Inc. reported earnings per share of ($0.21), beating the consensus estimate of ($0.26) by $0.05. The company had a negative net margin of 6,573.82% and a negative return on equity of 85.18%. Revenue for the quarter was $0.04 million, compared to the consensus estimate of $0.18 million. Analysts expect Synlogic to post EPS of -0.92 for the current fiscal year.
Various institutional investors have recently bought and sold shares of Synlogic Inc. Two Sigma Securities LLC purchased a stake in the company, Envestnet Asset Management Inc. increased its holdings, Millennium Management LLC also increased its holdings, Ensign Peak Advisors Inc. purchased a stake, and UBS Group AG purchased a stake. In total, 47.18% of the stock is owned by institutional investors.
Synlogic Inc. is a clinical-stage biopharmaceutical company in the United States, specializing in the discovery and development of synthetic biotics to treat metabolic and immunological diseases. The company’s pipeline includes drug candidates for the treatment of phenylketonuria, homocystinuria, enteric hyperoxaluria, and gout.
– Short Interest: the number of shares of a particular stock that have been sold short by investors.
– Short-Interest Ratio: the number of days it would take for all shorted shares to be covered based on the average daily trading volume.
– Earnings per Share (EPS): a financial metric that indicates the profitability of a company and is calculated as net income divided by the number of outstanding shares.
– Net Margin: a profitability ratio that shows how much profit a company makes per dollar of revenue.
– Return on Equity (ROE): a profitability ratio that indicates how much profit a company generates for each dollar of shareholder equity.
– Institutional Investors: organizations that invest large sums of money on behalf of their clients, such as mutual funds, pension funds, and hedge funds.
– Clinical-stage Biopharmaceutical Company: a company that is in the stage of developing and testing drugs for potential use in clinical trials.
– Synthetic Biotics: genetically engineered microbes designed to provide therapeutic benefits to patients.
– Phenylketonuria: an inherited disorder that causes an amino acid called phenylalanine to accumulate in the body, leading to brain damage and other health problems.
– Homocystinuria: an inherited disorder that affects the metabolism of the amino acid methionine, leading to various symptoms such as vision problems and skeletal abnormalities.
– Enteric Hyperoxaluria: a condition in which there is an excess of oxalate in the urine, leading to the formation of kidney stones.
– Gout: a type of arthritis characterized by severe pain, redness, and tenderness in the joints, often caused by a buildup of uric acid crystals.